Rob Flavell

I'm a physician scientist specialized in molecular imaging research, and nuclear medicine, and assistant professor at University of California, San Francisco

[Julie A Sosa, MD @Jasosamd]

The 2025 @AmThyroidAssn management guidelines for adult patients with differentiated thyroid cancer WENT ONLINE TODAY in @thyroidjournal, focusing on the patient journey, personalized/dynamic strategies & evidence! #MedTwitter @clinicalthyroid @ThyCaInc
https://t.co/lVvahsbRAR

[PSMA & Beyond Conference @PSMAconference]

Plan ahead! The next PSMA conference will be held March 26-27th, 2026. This is the go to conference for learning about clinical use of PSMA radioligand therapies and discussing future directions. It will again be held at the Luskin Center at UCLA.

[Freddy E Escorcia (@freddyeescorcia elsewhere) @freddyeescorcia]

Had fun collaborating with Ravi Patel (@RPatelMDPHD) & Steve Adler (@IRPatNIH) on this commentary highlighting Rob Flavell's (@flavell_rob) & @anilbidkar1's recent publication showing superior efficacy of alpha #radiopharmaceuticals therapy in micro v macromets

👇

[Rob Flavell @flavell_rob]

Congrats to @anilbidkar1 on leading this work integrating alpha particle microdosimetry with therapeutic efficacy, and demonstrating the potential of CD46 RPT in the context of disseminated preclinical models.

[UroToday.com @urotoday]

Effective treatment of disseminated #ProstateCancer using CD46-targeted 225Ac therapy. #AuthorCommentary New hope for PSMA-negative #ProstateCancer: CD46-targeted 225Ac alpha therapy shows strong preclinical efficacy in disseminated mCRPC models. Early treatment = better outcomes. A promising path for patients with liver mets & low PSMA expression. #ReadNow > https://t.co/VDVgttiBYT @anilbidkar1 @knaidubobba @jonchou05

[Freddy E Escorcia (@freddyeescorcia elsewhere) @freddyeescorcia]

It's been a while since I posted on some of the ☢️ #radiopharmaceuticals ☢️ work we've been brewing.

Let's fix that...

🧵👇
1/5

[Anil Bidkar @anilbidkar1]

Exciting news from Flavell Lab(@flavell_rob)! Our latest study on CD46-targeted Actinium-225 alpha particle therapy for disseminated prostate cancer is now online in Clinical Cancer Research. Read it @CCR_AACR: https://t.co/DBMr6nwbLb #ProstateCancer #Ac225 #CD46 #Theranostics

[UCSF Imaging @UCSFimaging]

The 9th Annual PICT Symposium is happening on 3/26! Explore advancements in #Immunotherapy, #Theranostics & #AI in Cancer Imaging, with talks & posters by leading experts & rising researchers.

Abstracts due Feb 21, 2025.

Register to attend & present: https://t.co/fEZREECi1C

[SNMMI @SNM_MI]

A big victory for patients and the nuclear medicine field! CMS announced the unbundling of diagnostic radiopharmaceuticals at the $630 level, opening access to nuclear medicine scans for patients who need it the most. More here: https://t.co/J5Vwygt3fX

[Rob Flavell @flavell_rob]

@DrMHofman @PCF_Science @drlouiseemmett @LewisLabMSKCC @RenuEapen @anna_t_g @AzadOncology @declangmurphy @AnnetteVDHeyden @pj_physics @MHaskali @SandhuShahneen Great session!

[UCSF Imaging @UCSFimaging]

New in #Theranostics from @UCSFimaging's Drs. Anil Bidkar (@anilbidkar1), Luann Zerefa, Surekha Yadav (@shiningsurekha), Henry VanBrocklin & Robert Flavell (@flavell_rob): "Actinium-225 targeted alpha particle therapy for prostate cancer." https://t.co/l5fFVbIMB5

[Michael Peluso, MD @MichaelPelusoMD]

New @UCSF #LIINC paper: immune activation & viral persistence in tissue up to 2 years post-COVID. Found double-stranded RNA in #LongCOVID, suggesting active reservoir persists and evades immune clearance. Thanks @polybioRF, @NIH for support. @ScienceTM

https://t.co/30Eb0juBN7

[PolyBio @polybioRF]

Breaking!: Research published today in Science Translational Medicine and supported by PolyBio Research Foundation shows that the #SARS-CoV-2 virus can chronically persist in the gut of patients with long COVID for over 2 years: https://t.co/rYAT9BHKqe

[Waggoner Lab @LabWaggoner]

Total-body PET imaging and microscopy analysis of rectosigmoid biopsies reveal prolonged T cell activation and SARS-CoV-2 RNA persistence following COVID-19
https://t.co/RXteOQ5sVt
@MichaelPelusoMD @Dylan_Ryder1 @flavell_rob

[Rob Flavell @flavell_rob]

@LewisLabMSKCC @charlesrudin @Tendler_S @morr316 @lisabodei Congratulations! Great work.

[Tejal A. Desai @TejalADesai]

Excited that our new paper is out! Led by Deblin Jana @brownengin @DesaiLabUCSF in collaboration with @flavell_rob @UCSFimaging , we show enhanced prostate specific membrane antigen targeting by DNA scaffolded nanoparticle ligand presentation @acsnano https://t.co/LXLibMpoUx

[Norbert Galldiks @galldiks]

Happy to share our latest work of the PET/RANO group:
https://t.co/jDPa4PLEl4
Was exciting to prepare this guideline with so many world experts in the field!
@UKKoeln
@fz_juelich
#btsm #NeuroOncology #PETImaging #Neuroimaging #Meningioma

[Susanna I Lee @SusannaLeeRad]

Incidental hot lesions on prostate-specific membrane antigen (PSMA) PET. Should we be working them up?
#RadAdv @RSNA @OUPMedicine @UCSFimaging
https://t.co/fO8xoejiDG

[Rob Flavell @flavell_rob]

@NataliaHerAlv @SNM_MI @LewisLabMSKCC Great presentation!

[UroToday.com @urotoday]

🔬 Exciting insights at the 2024 @PSMAconference! Watch Robert Flavell @UCSF delve into PSMA pharmacology & its pivotal role in #ProstateCancer mgmt. Learn how PSMA PET revolutionizes diagnosis & guides therapy for metastatic cases > https://t.co/HlmnkLMynh #2024PSMAConference

[UroToday.com @urotoday]

At the #2024PSMAConference, @flavell_rob discussed the promise of antibody-based radiopharmaceuticals for prostate cancer, highlighting their high specificity and addressing challenges like long half-lives. #WatchNow on UroToday > https://t.co/nIbU9ZbKmh @PSMAconference